 It has been nearly one year since I took a good look at Lantheus Holdings, but PYLARIFYs approval has forced me to reassess the ticker and my investment strategy. PYLARIFY has the potential to be a game-changer in prostate cancer diagnosis and improve patient outcomes. The company has been hard at work preparing for launch in the USA. 